Loading
institutionsInstitution
Istituto Oncologico Veneto IRCCS
The Veneto region's OECI-accredited comprehensive cancer centre in Padua, strong in breast cancer trials, melanoma and tumour immunology.
Also called: IOVVeneto Institute of Oncology
Overview
Founded in 2005, the Istituto Oncologico Veneto is the IRCCS cancer institute of the Veneto region and coordinates the regional oncology network; it is accredited by the OECI as a comprehensive cancer centre. Pierfranco Conte and Valentina Guarneri's breast oncology group led the ShortHER trial of trastuzumab duration and many neoadjuvant studies, the melanoma unit is a leading Italian immunotherapy trial site, and Vincenzo Bronte's immunology programme is known for myeloid-derived suppressor cells. The institute runs gastrointestinal, thoracic and gynaecological oncology, radiotherapy and nuclear medicine across Padua and Castelfranco Veneto, with a phase 1 unit and the University of Padua's oncology school.
Location
Padua, IT
Type
cancer center · Università degli Studi di Padova
Website
Newsweek 2026 oncology rank
Not in top 300 listing used
OnCo score
#269 · 24 points (0 Newsweek + 0 NCI + 24 from 12 linked objects) · ranking
Research output
From OpenAlex, oncology works in the last five years (2022 to 2026, current year in progress); counted on 2026-09-15.
Matched to Istituto Oncologico Veneto, including child institutions. 962 works · 12,326 citations · 71% open access · 20% clinical trials · 2% reviews.
Oncology works per year
1992022
1912023
2162024
2222025
1342026
Most works
- Sara Lonardi213 works
- Chiara Cremolini117 works
- Francesca Bergamo111 works
- Filippo Pietrantonio82 works
- Matteo Fassan75 works
- Valentina Guarneri68 works
- Vanna Chiarion‐Sileni54 works
- Daniele Rossini50 works
- Giulia Pasello49 works
- Carlotta Antoniotti48 works
Most cited
- Breast cancer trials
- Melanoma immunotherapy
- Tumour immunology (myeloid cells)
- Veneto oncology network
- Phase 1 unit
Antonio Rosato
Scientific Director
Tumour immunologyCancer immunotherapyTranslational research
Immunologist and Scientific Director of the Istituto Oncologico Veneto, leading its translational cancer research.
Patrizia Simionato
General Director
Health administrationCancer institute management
General Director of the Istituto Oncologico Veneto, the Veneto region's IRCCS cancer institute in Padua.
Similar pages
- PersonCarlo Cimbri
Shares IEO (European Institute of Oncology), Organisation of European Cancer Institutes.
- TrialA Study Evaluating the Efficacy and Safety of Adjuvant Atezolizumab or Placebo and Trastuzumab Emtansine for Participants With HER2-Positive Breast Cancer at High Risk of Recurrence Following Preoperative Therapy
Shares Trastuzumab, HER2-positive breast cancer, Monoclonal antibodies, Immune checkpoint inhibitors.
- IdeaTime immunotherapy to the moment targeted drugs make tumours visible
Shares CDK4/6 inhibitors, Melanoma, HR-positive / HER2-negative breast cancer, Immune checkpoint inhibitors.
- TrialPATINA
Shares CDK4/6 inhibitors, Trastuzumab, HER2-positive breast cancer, HR-positive / HER2-negative breast cancer.
- TrialTL938 and Trastuzumab for Patients With HER2-positive Metastatic Colorectal Cancer
Shares Trastuzumab, Monoclonal antibodies, Colorectal cancer.
- InstitutionHospital del Mar / Hospital del Mar Research Institute
Shares Trastuzumab, HER2-positive breast cancer, Monoclonal antibodies, HR-positive / HER2-negative breast cancer.
- TrialTQB2930 Injection for the Treatment of HER2-positive Advanced Breast Cancer
Shares Trastuzumab, HER2-positive breast cancer, Monoclonal antibodies.
- IdeaWHO prequalification plus pooled demand to push biosimilar prices below 10% of the originator
Shares Trastuzumab, HER2-positive breast cancer, Monoclonal antibodies.
cancers
fronts
technologies
drugs
ApprovedMonoclonal antibody (anti-HER2)
Trastuzumab · Herceptin (and biosimilars, Phesgo with pertuzumab)